The mRNA expression of <em>Il6</em> and <em>Pdcd1</em> are predictive and protective factors for doxorubicin‑induced cardiotoxicity

Kanno,Syu-Ichi; Hara,Akiyoshi

doi:10.3892/mmr.2020.11752

The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin‑induced cardiotoxicity

Authors:
- Syu-Ichi Kanno
- Akiyoshi Hara
View Affiliations

Affiliations: Department of Clinical Pharmacotherapeutics, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi 981‑8558, Japan
Published online on: December 3, 2020 https://doi.org/10.3892/mmr.2020.11752
Article Number: 113
Copyright: © Kanno et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anthracyclines, such as doxorubicin (DOX), have been widely used in the treatment of a number of different solid and hematological malignancies. However, these drugs can inflict cumulative dose‑dependent and irreversible damage to the heart, and can occasionally lead to heart failure. The cardiotoxic susceptibility varies among patients treated with anthracycline, and delays in the recognition of cardiotoxicity can result in poor prognoses. Accordingly, if the risk of cardiotoxicity could be predicted prior to drug administration, it would aid in safer and more effective chemotherapy treatment. The present study was carried out to identify genes that can predict DOX‑induced cardiotoxicity (DICT). In an in vivo study, mice cumulatively treated with DOX demonstrated increases in serum levels of cardiac enzymes (aspartate aminotransferase, lactate dehydrogenase, creatine kinase MB isoenzyme and troponin T), in addition to decreases in body and heart weights. These changes were indicative of DICT, but the severity of these effects varied among individual mice. In the current study, the correlation in these mice between the extent of DICT and circulating blood concentrations of relevant transcripts before DOX administration was analyzed. Among various candidate genes, the plasma mRNA levels of the genes encoding interleukin 6 (Il6) and programmed cell death 1 (Pdcd1) in blood exhibited significant and positive correlations with the severity of DICT. In an in vitro study using cardiomyocyte H9c2 cells, knockdown of Il6 or Pdcd1 by small interfering RNA was revealed to enhance DOX‑induced apoptosis, as determined by luminescent assays. These results suggested that the levels of transcription of Il6 and Pdcd1 in cardiomyocytes serve a protective role against DICT, and that the accumulation of these gene transcripts in blood is a predictive marker for DICT. To the best of our knowledge, this is the first report to demonstrate a role for Il6 and Pdcd1 mRNA expression in DICT.

View Figures

View References

1	McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM and Yellon DM: Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 31:63–75. 2017. View Article : Google Scholar : PubMed/NCBI
2	Nebigil CG and Désaubry L: Updates in anthracycline-mediated cardiotoxicity. Front Pharmacol. 9:12622018. View Article : Google Scholar : PubMed/NCBI
3	Swain SM, Whaley FS and Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 97:2869–2879. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ewer MS and Ewer SM: Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat Rev Cardiol. 7:564–575. 2010. View Article : Google Scholar : PubMed/NCBI
5	Jungsuwadee P: Doxorubicin-induced cardiomyopathy: An update beyond oxidative stress and myocardial cell death. Cardiovasc Reg Med. 3:e11272016.
6	Ohtani K, Fujino T, Ide T, Funakoshi K, Sakamoto I, Hiasa KI, Higo T, Kamezaki K, Akashi K and Tsutsui H: Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity. Clin Res Cardiol. 108:600–611. 2019. View Article : Google Scholar : PubMed/NCBI
7	Raj S, Franco VI and Lipshultz SE: Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med. 16:3152014. View Article : Google Scholar : PubMed/NCBI
8	Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, et al: 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. Kardiol Pol. 74:1193–1233. 2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
9	Glass CK and Mitchell RN: Winning the battle, but losing the war: Mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. Cardiovasc Pathol. 30:55–63. 2017. View Article : Google Scholar : PubMed/NCBI
10	Totzeck M, Mincu RI, Heusch G and Rassaf T: Heart failure from cancer therapy: Can we prevent it? ESC Heart Fail. 6:856–862. 2019. View Article : Google Scholar : PubMed/NCBI
11	Hadi N, Yousif NG, Al-amran FG, Huntei NK, Mohammad BI and Ali SJ: Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response. BMC Cardiovasc Disord. 12:632012. View Article : Google Scholar : PubMed/NCBI
12	Yamanaka S, Tatsumi T, Shiraishi J, Mano A, Keira N, Matoba S, Asayama J, Fushiki S, Fliss H and Nakagawa M: Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol. 41:870–878. 2003. View Article : Google Scholar : PubMed/NCBI
13	Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, Rubino M, Veglia F, Fiorentini C and Cipolla CM: Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 55:213–220. 2010. View Article : Google Scholar : PubMed/NCBI
14	Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, et al: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. 27:911–939. 2014. View Article : Google Scholar : PubMed/NCBI
15	Cappetta D, Esposito G, Coppini R, Piegari E, Russo R, Ciuffreda LP, Rivellino A, Santini L, Rafaniello C, Scavone C, et al: Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. Br J Pharmacol. 174:3696–3712. 2017. View Article : Google Scholar : PubMed/NCBI
16	Henriksen PA: Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention. Heart. 104:971–977. 2018. View Article : Google Scholar : PubMed/NCBI
17	Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, et al: Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 82:683–695. 2016. View Article : Google Scholar : PubMed/NCBI
18	Nair AB and Jacob S: A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 7:27–31. 2016. View Article : Google Scholar : PubMed/NCBI
19	Neilan TG, Jassal DS, Scully MF, Chen G, Deflandre C, McAllister H, Kay E, Austin SC, Halpern EF, Harmey JH and Fitzgerald DJ: Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J. 27:1251–1256. 2006. View Article : Google Scholar : PubMed/NCBI
20	Jenkins GR, Lee T, Moland CL, Vijay V, Herman EH, Lewis SM, Davis KJ, Muskhelishvili L, Kerr S, Fucoe JC and Desai VG: Sex-related differential susceptibility to doxorubicin-induced cardiotoxicity in B6C3F₁ mice. Toxicol Appl Pharmacol. 310:159–174. 2016. View Article : Google Scholar : PubMed/NCBI
21	Vijay V, Moland CL, Han T, Fuscoe JC, Lee T, Herman EH, Jenkins GR, Lewis SM, Cummings CA, Gao Y, et al: Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice. Toxicol Appl Pharmacol. 295:68–84. 2016. View Article : Google Scholar : PubMed/NCBI
22	Kanno S, Ishikawa M, Takayanagi M, Takayanagi Y and Sasaki K: Potentiation of acetaminophen hepatotoxicity and mortality by doxapram in mice. Biol Pharm Bull. 21:934–937. 1998. View Article : Google Scholar : PubMed/NCBI
23	Kanno S, Tomizawa A, Hiura T, Osanai Y, Kakuta M, Kitajima Y, Koiwai K, Ohtake T, Ujibe M and Ishikawa M: Melatonin protects on toxicity by acetaminophen but not on pharmacological effects in mice. Biol Pharm Bull. 29:472–476. 2006. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Blankenberg FG, Tait JF and Strauss HW: Apoptotic cell death: Its implications for imaging in the next millennium. Eur J Nucl Med. 27:359–367. 2000. View Article : Google Scholar : PubMed/NCBI
26	Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden JL, Steinmetz N and van Eck-Smit BL: Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med. 45:842–848. 2004.PubMed/NCBI
27	Schwartz RG, Jain D and Storozynsky E: Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J Nucl Cardiol. 20:443–464. 2013. View Article : Google Scholar : PubMed/NCBI
28	Salvesen GS and Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell. 91:443–446. 1997. View Article : Google Scholar : PubMed/NCBI
29	He H, Liu C, Wu Y, Zhang X, Fan J and Cao Y: A multiscale physiologically-based pharmacokinetic model for doxorubicin to explore its mechanisms of cytotoxicity and cardiotoxicity in human physiological contexts. Pharm Res. 35:1742018. View Article : Google Scholar : PubMed/NCBI
30	Eppstein DA, Kurahara CG, Bruno NA and Terrell TG: Prevention of doxorubicin-induced hematotoxicity in mice by interleukin 1. Cancer Res. 49:3955–3960. 1989.PubMed/NCBI
31	Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM, Chan WY, Zhao H, To MY, Fok TF, et al: Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation. 113:2211–2220. 2006. View Article : Google Scholar : PubMed/NCBI
32	Liu X, Chen Z, Chua CC, Ma YS, Youngberg GA, Hamdy R and Chua BH: Melatonin as an effective protector against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 283:H254–H263. 2002. View Article : Google Scholar : PubMed/NCBI
33	Montgomery MD, Chan T, Swigart PM, Myagmar BE, Dash R and Simpson PC: An alpha-1A adrenergic receptor agonist prevents acute doxorubicin cardiomyopathy in male mice. PLoS One. 12:e01684092017. View Article : Google Scholar : PubMed/NCBI
34	Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W and Bolli R: IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res. 64:61–71. 2004. View Article : Google Scholar : PubMed/NCBI
35	McGinnis GR, Ballmann C, Peters B, Nanayakkara G, Roberts M, Amin R and Quindry JC: Interleukin-6 mediates exercise preconditioning against myocardial ischemia reperfusion injury. Am J Physiol Heart Circ Physiol. 308:H1423–H1433. 2015. View Article : Google Scholar : PubMed/NCBI
36	Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N and Honjo T: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 291:319–322. 2001. View Article : Google Scholar : PubMed/NCBI
37	Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N and Honjo T: Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 9:1477–1483. 2003. View Article : Google Scholar : PubMed/NCBI
38	Qin XH, Lee VW, Wang YP, Zheng GP, Wang Y, Alexander SI and Harris DC: A protective role for programmed death 1 in progression of murine adriamycin nephropathy. Kidney Int. 70:1244–1250. 2006. View Article : Google Scholar : PubMed/NCBI
39	Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR and Heads RJ: IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res. 69:164–177. 2006. View Article : Google Scholar : PubMed/NCBI
40	Sheng CC, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, Croce K, Kim G and Moslehi J: 21st Century cardio-oncology: Identifying cardiac safety signals in the era of personalized medicine. JACC Basic Transl Sci. 1:386–398. 2016. View Article : Google Scholar : PubMed/NCBI
41	Zhang YW, Shi J, Li YJ and Wei L: Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz). 57:435–445. 2009. View Article : Google Scholar : PubMed/NCBI
42	Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE and Sanders SP: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 324:808–815. 1991. View Article : Google Scholar : PubMed/NCBI
43	Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M and Kinoshita M: Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 31:391–398. 1998. View Article : Google Scholar : PubMed/NCBI
44	Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH and Entman ML: Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation. 99:546–551. 1999. View Article : Google Scholar : PubMed/NCBI
45	Sun Y: Oxidative stress and cardiac repair/remodeling following infarction. Am J Med Sci. 334:197–205. 2007. View Article : Google Scholar : PubMed/NCBI
46	Neri M, Fineschi V, Di Paolo M, Pomara C, Riezzo I, Turillazzi E and Cerretani D: Cardiac oxidative stress and inflammatory cytokines response after myocardial infarction. Curr Vasc Pharmacol. 13:26–36. 2015. View Article : Google Scholar : PubMed/NCBI
47	Li JY, He Y, Ke HH, Jin Y, Jiang ZY and Zhong GQ: Plasma oxidative stress and inflammatory biomarkers are associated with the sizes of the left atrium and pulmonary vein in atrial fibrillation patients. Clin Cardiol. 40:89–94. 2017. View Article : Google Scholar : PubMed/NCBI
48	Hartman MHT, Groot HE, Leach IM, Karper JC and van der Harst P: Translational overview of cytokine inhibition in acute myocardial infarction and chronic heart failure. Trends Cardiovasc Med. 28:369–379. 2018. View Article : Google Scholar : PubMed/NCBI
49	Okazaki T, Maeda A, Nishimura H, Kurosaki T and Honjo T: PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA. 98:13866–13871. 2001. View Article : Google Scholar : PubMed/NCBI
50	Berthiaume JM and Wallace KB: Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovasc Toxicol. 7:178–191. 2007. View Article : Google Scholar : PubMed/NCBI
51	Holmgren G, Synnergren J, Bogestål Y, Améen C, Åkesson K, Holmgren S, Lindahl A and Sartipy P: Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology. 328:102–111. 2015. View Article : Google Scholar : PubMed/NCBI
52	Thompson KL, Rosenzweig BA, Zhang J, Knapton AD, Honchel R, Lipshultz SE, Retief J, Sistare FD and Herman EH: Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol. 66:303–314. 2010. View Article : Google Scholar : PubMed/NCBI
53	Todorova VK, Beggs ML, Delongchamp RR, Dhakal I, Makhoul I, Wei JY and Klimberg VS: Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model. PLoS One. 7:e483982012. View Article : Google Scholar : PubMed/NCBI
54	Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E and Shohet RV: Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 290:H1098–H1102. 2006. View Article : Google Scholar : PubMed/NCBI
55	Zhao WJ, Wei SN, Zeng XJ, Xia YL, Du J and Li HH: Gene expression profiling identifies the novel role of immunoproteasome in doxorubicin-induced cardiotoxicity. Toxicology. 333:76–88. 2015. View Article : Google Scholar : PubMed/NCBI
56	Bertinchant JP, Polge A, Juan JM, Oliva-Lauraire MC, Giuliani I, Marty-Double C, Burdy JY, Fabbro-Peray P, Laprade M, Bali JP, et al: Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta. 329:39–51. 2003. View Article : Google Scholar : PubMed/NCBI
57	Shan K, Lincoff AM and Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med. 125:47–58. 1996. View Article : Google Scholar : PubMed/NCBI
58	Gharib MI and Burnett AK: Chemotherapy-induced cardiotoxicity: Current practice and prospects of prophylaxis. Eur J Heart Fail. 4:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
59	Ganatra S, Nohria A, Shah S, Groarke JD, Sharma A, Venesy D, Patten R, Gunturu K, Zarwan C, Neilan TG, et al: Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: A consecutive case series. Cardiooncology. 5:12019.PubMed/NCBI
60	Langer SW: Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res. 6:357–363. 2014. View Article : Google Scholar : PubMed/NCBI